NCT06406426View on ClinicalTrials.gov

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

September 1, 2026

Conditions
Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER